<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01296542</url>
  </required_header>
  <id_info>
    <org_study_id>2011-BV-C</org_study_id>
    <nct_id>NCT01296542</nct_id>
  </id_info>
  <brief_title>A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery</brief_title>
  <official_title>A Comparison of Prophylactic Antibacterial Efficacy of Besivance Versus VIGAMOX Administered for Three Days and One Hour Prior to Phacoemulsification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bucci Laser Vision Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bucci Laser Vision Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare antibacterial efficacy of Besivance versus VIGAMOX for decreasing bacteria of the&#xD;
      conjunctiva and lid margins in cataract patients prior to surgery after both 1 hour and 3&#xD;
      days of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 Days</measure>
    <time_frame>Following 3 days of antibiotic drops topically instilled</time_frame>
    <description>Lid and Conjunctival cultures will be taken to measure bacterial colonization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>VIGAMOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Besivance</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin Ophthalmic</intervention_name>
    <arm_group_label>VIGAMOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifloxacin Ophthalmic</intervention_name>
    <arm_group_label>Besivance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman 18 years of age or older.&#xD;
&#xD;
          -  Physically capable of instilling eye drop or have an appropriate person available to&#xD;
             assist in administration of eye drops 4 times a day.&#xD;
&#xD;
          -  Scheduled for phacoemulsification with intraocular lens (IOL) implantation for the&#xD;
             treatment of cataract.&#xD;
&#xD;
          -  Meet the American Society of Anesthesiology (ASA) physical status I, II, or III and be&#xD;
             medically cleared for surgery.&#xD;
&#xD;
          -  Willing to adhere to the prohibitions and restrictions specified in this protocol.&#xD;
&#xD;
          -  Subjects must have signed an informed consent document indicating that they understand&#xD;
             the purpose of and procedures required for the study and are willing to participate in&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or contraindication to the test article(s) or their components.&#xD;
&#xD;
          -  Presence of any abnormality or significant illness in the eye that in the&#xD;
             investigator's opinion could affect the subject's health or the study parameters.&#xD;
&#xD;
          -  Presence of an active ocular infection (bacterial, viral or fungal), or positive&#xD;
             history of ocular herpetic infection.&#xD;
&#xD;
          -  History of any significant illness that could be expected to interfere with the study&#xD;
             parameters. Any condition that, in the opinion of the investigator, would compromise&#xD;
             the well-being of the subject or the study.&#xD;
&#xD;
          -  Use of disallowed therapies (systemic or topical):&#xD;
&#xD;
               -  Fluoroquinolone anti-infective agents (systemic or topical) within 1 week of&#xD;
                  Visit 1 or anytime after Visit 1 for the duration of the study.&#xD;
&#xD;
          -  Use of contact lenses for one week prior to the study and for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Received an experimental drug or used an experimental medical device within 21 days&#xD;
             before the planned start of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank A. Bucci, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucci Laser Vision Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bucci Laser Vision Institute</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 14, 2011</study_first_submitted>
  <study_first_submitted_qc>February 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2011</study_first_posted>
  <results_first_submitted>January 23, 2013</results_first_submitted>
  <results_first_submitted_qc>December 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 8, 2020</results_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bucci Laser Vision Institute</investigator_affiliation>
    <investigator_full_name>Frank A. Bucci, Jr., M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Besifloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VIGAMOX</title>
          <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
        </group>
        <group group_id="P2">
          <title>Besivance</title>
          <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VIGAMOX</title>
          <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
        </group>
        <group group_id="B2">
          <title>Besivance</title>
          <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 Days</title>
        <description>Lid and Conjunctival cultures will be taken to measure bacterial colonization.</description>
        <time_frame>Following 3 days of antibiotic drops topically instilled</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VIGAMOX</title>
            <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
          </group>
          <group group_id="O2">
            <title>Besivance</title>
            <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 Days</title>
          <description>Lid and Conjunctival cultures will be taken to measure bacterial colonization.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VIGAMOX</title>
          <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
        </group>
        <group group_id="E2">
          <title>Besivance</title>
          <description>Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frank A. Bucci Jr., MD</name_or_title>
      <organization>Bucci Laser Vision</organization>
      <phone>570-825-5949</phone>
      <email>buccivision@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

